Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McGill University
$105,000.00
Warfarin therapy in venous thromboembolism: using causal inference methods to assess the impact on recurrence, bleeding, and mortality
EF 2013-14
Résumé
Venous thromboembolism (VTE) is the third leading cause of death from cardiovascular disease, after heart attack and stroke. It involves the formation of a blood clot, typically in a deep vein of the leg, which may dislodge and travel to the lungs. To prevent complications, patients with VTE are treated with anticoagulants (i.e., blood thinners). These drugs are effective at reducing the risk of another VTE event while the patient is on treatment; however they are also associated with increased risk of bleeding. Thus, patients should be frequently monitored to minimize adverse effects.
This project will assess the impact of warfarin (the mainstay of therapy for long-term treatment of VTE) on adverse outcomes using data on patients from Canada and the United Kingdom. One objective is to determine patient characteristics and risk factors which predict adverse outcomes, including a second VTE event, bleeding, and death from any cause. This information is essential to identify patient groups who are at the highest risk of adverse events and who may require tighter laboratory monitoring. A second objective is to estimate the effect of warfarin on the development of a second VTE event, accounting for the impact of bleeding. This information is important to assess the clinical effectiveness of warfarin. Given that warfarin affects the risk of bleeding, which in turn affects the next dose of warfarin as well as the risk of VTE events, estimation of the effect of interest requires more sophisticated tools compared to conventional statistical techniques. Thus, causal inference methodology will be used to address this question.
Overall importance: This project will provide new information on adverse outcomes of the most widely used treatment for patients with VTE and its effectiveness, and will help identify high-risk subgroups, who may benefit most from frequent laboratory monitoring in order to minimize the risk of adverse outcomes and to improve the health of patients.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
307732
Name
Rushani Dinela
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
Warfarin therapy in venous thromboembolism: using causal inference methods to assess the impact on recurrence, bleeding, and mortality
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Adverse Drug Effects; Causal Inference; High-Dimensional Propensity Score; Marginal Structural Model; Pharmacoepidemiology; Population-Based Research; Predictive Model; Venous Thromboembolism; Warfarin Therapy
Abstract
Venous thromboembolism (VTE) is the third leading cause of death from cardiovascular disease, after heart attack and stroke. It involves the formation of a blood clot, typically in a deep vein of the leg, which may dislodge and travel to the lungs. To prevent complications, patients with VTE are treated with anticoagulants (i.e., blood thinners). These drugs are effective at reducing the risk of another VTE event while the patient is on treatment; however they are also associated with increased risk of bleeding. Thus, patients should be frequently monitored to minimize adverse effects.
This project will assess the impact of warfarin (the mainstay of therapy for long-term treatment of VTE) on adverse outcomes using data on patients from Canada and the United Kingdom. One objective is to determine patient characteristics and risk factors which predict adverse outcomes, including a second VTE event, bleeding, and death from any cause. This information is essential to identify patient groups who are at the highest risk of adverse events and who may require tighter laboratory monitoring. A second objective is to estimate the effect of warfarin on the development of a second VTE event, accounting for the impact of bleeding. This information is important to assess the clinical effectiveness of warfarin. Given that warfarin affects the risk of bleeding, which in turn affects the next dose of warfarin as well as the risk of VTE events, estimation of the effect of interest requires more sophisticated tools compared to conventional statistical techniques. Thus, causal inference methodology will be used to address this question.
Overall importance: This project will provide new information on adverse outcomes of the most widely used treatment for patients with VTE and its effectiveness, and will help identify high-risk subgroups, who may benefit most from frequent laboratory monitoring in order to minimize the risk of adverse outcomes and to improve the health of patients.
Competitiondate
201310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Rushani, Dinela
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~